Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cell Signaling Research

Executive Summary: Y-27632 dihydrochloride is a well-characterized, cell-permeable inhibitor of ROCK1 and ROCK2, showing IC₅₀ values of approximately 140 nM and Ki of 300 nM, respectively, under standard in vitro conditions (ApexBio product page). It exhibits over 200-fold selectivity against non-ROCK kinases such as PKC and PKA, ensuring targeted modulation of the Rho/ROCK signaling pathway. This compound efficiently inhibits Rho-mediated formation of stress fibers and modulates cell cycle progression from G1 to S phase. Y-27632 dihydrochloride is routinely used in cancer biology, stem cell research, and studies of cytoskeletal dynamics. Its effects are highly reproducible in both in vitro and in vivo models, supporting its role as a research standard (Guo et al., 2024).

Biological Rationale

ROCK1 and ROCK2 are serine/threonine kinases that act downstream of Rho GTPases, regulating actomyosin contractility, cell shape, and motility. Rho/ROCK signaling is central to cytoskeletal organization, cellular tension, and cell cycle control. Aberrant ROCK activity is implicated in cancer invasion, fibrosis, and stem cell viability loss (Guo et al., 2024). Selective pharmacological inhibition using Y-27632 dihydrochloride enables precise perturbation of these pathways, facilitating mechanistic studies in both normal and pathological contexts.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride acts as an ATP-competitive inhibitor, binding the catalytic domains of ROCK1 (IC₅₀ ≈140 nM) and ROCK2 (Ki ≈300 nM), with more than 200-fold selectivity over protein kinases such as PKC, cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK) (ApexBio). The compound blocks phosphorylation events downstream of RhoA activation, preventing stress fiber and focal adhesion assembly. This leads to cytoskeletal relaxation, inhibition of cytokinesis, and altered cell migration. Y-27632 further modulates cell cycle transitions, particularly G1/S progression, and impairs tumor cell invasion by disrupting actomyosin contractility.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a Ki of 300 nM in enzymatic assays (ApexBio).
• Exhibits >200-fold selectivity versus PKC, PKA, MLCK, and PAK kinases, minimizing off-target effects (ApexBio).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a concentration-dependent manner (10–100 µM, 24–72 h) (Guo et al., 2024).
• Suppresses tumor invasion and metastasis in mouse cancer models, with significant reduction in pathological structures after daily intraperitoneal administration (10 mg/kg, 2–4 weeks) (Guo et al., 2024).
• Enhances survival and expansion of human embryonic stem cells and iPSCs without feeder layers (10 µM, 24–48 h) (Y-27632.com).

This article extends the scope of previous reviews by providing current quantitative benchmarks and clarifying optimal workflows for Y-27632 dihydrochloride in advanced cytoskeletal research.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is primarily used in:

• Disruption of Rho-mediated stress fiber formation in cytoskeletal studies.
• Enhancement of stem cell viability and colony expansion in feeder-free cultures.
• Suppression of tumor invasion and metastasis in preclinical cancer models.
• Cell proliferation assays and studies of cytokinesis inhibition.
• Modulation of Rho/ROCK signaling pathways in tissue regeneration and repair (Guo et al., 2024).

While prior summaries highlighted general uses, this article provides explicit selectivity data and discusses key concentration ranges for optimal effect.

Common Pitfalls or Misconceptions

• Not all kinases are inhibited: Y-27632 dihydrochloride is highly selective for ROCK1/2 and does not significantly inhibit PKC, PKA, MLCK, or PAK at typical working concentrations (ApexBio).
• Not a universal anti-proliferative agent: Its effects are cell context-dependent and not all cell types respond with reduced proliferation.
• Not suitable for long-term solution storage: Aqueous or DMSO stock solutions should be stored below -20°C for short periods only; degradation occurs with long-term storage.
• Does not replace genetic knockdown: Pharmacological inhibition is reversible and may not fully phenocopy genetic knockout of ROCK1/2.
• Not a direct peroxisome modulator: While Y-27632 can alter cytoskeletal dynamics relevant to peroxisome trafficking, it does not directly regulate peroxisome biogenesis or PPAR signaling, as clarified in Guo et al., 2024.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a stable solid (SKU: A3008) and should be stored desiccated at ≤4°C. For stock preparation:

• Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at 25°C.
• Enhance dissolution by warming to 37°C or using an ultrasonic bath.
• Recommended working concentrations range from 1–50 µM for most cell-based assays.
• Stock solutions (<1 mM) can be stored below -20°C for several months; avoid repeated freeze-thaw cycles.

For detailed troubleshooting and protocol optimization, see comparative workflows in this review, which this article updates by including newly published in vivo benchmarks.

Conclusion & Outlook

Y-27632 dihydrochloride remains an indispensable tool for dissecting Rho/ROCK signaling, cytoskeletal architecture, and stem cell regulation. Its high selectivity, reproducible efficacy, and well-defined parameters underpin its widespread adoption in cell biology and cancer research. Continued integration with advanced disease models and combinatorial screening platforms is expected to expand its translational impact (Guo et al., 2024). For product details and ordering, visit the Y-27632 dihydrochloride product page.